Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Before High-Dose Chemotherapy BEAM With Autologous Stem Cell Transplantation (ASCT)

Trial Profile

Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Before High-Dose Chemotherapy BEAM With Autologous Stem Cell Transplantation (ASCT)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Obinutuzumab (Primary) ; Cisplatin; Cytarabine; Dexamethasone; Pegfilgrastim
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms GIOTTO
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 15 Jun 2016 Planned End Date changed from 1 Jun 2017 to 1 Oct 2021.
    • 15 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top